Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults
Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.43.7.1686
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 1999
Authors
Publisher
American Society for Microbiology